PGx6652: Genetic Evaluation of Pazopanib –Related Hepatotoxicity (117365)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/16864
• EU PAS number:
  EUPAS6189
• Study ID:
  16864
• Official title and acronym:
  PGx6652: Genetic Evaluation of Pazopanib –Related Hepatotoxicity (117365)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study status:
  Finalised

Research institution and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned: 02/11/2012

Actual: 02/11/2012

Study start date

Planned: 16/11/2012

Actual: 16/11/2012

Date of final study report

Planned: 31/07/2014

Actual: 20/05/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Study protocol

Initial protocol

veg117365-reporting-and-analysis-plan-redact

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)